Sandimmun Optoral ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
53Sjogren syndrome2
113Muscular dystrophy1

53. Sjogren syndrome


Clinical trials : 283 Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01693393
(ClinicalTrials.gov)
March 201014/9/2012Low Dose Cyclosporin A in Primary Sjögren SyndromeA Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sjögren SyndromeSjögren´s SyndromeDrug: Cyclosporine ACharite University, Berlin, GermanyNULLCompleted18 Years75 YearsBoth30Phase 2Germany
2EUCTR2009-013976-38-DE
(EUCTR)
07/12/2009Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) - CypressPhase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) - Cypress Primary Sjögren's Syndrome
MedDRA version: 12.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome
Trade Name: Sandimmun Optoral
Product Name: Sandimmun Optoral
INN or Proposed INN: CICLOSPORIN
Trade Name: Sandimmun Optoral
Product Name: Sandimmun Optoral
INN or Proposed INN: CICLOSPORIN
Trade Name: Sandimmun Optoral
Product Name: Sandimmun Optoral
INN or Proposed INN: CICLOSPORIN
Charité Berlin, Department of rheumatologyCharité Berlin, department of rheumatology;Charité Berlin, department of rheumatologyAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Germany

113. Muscular dystrophy


Clinical trials : 622 Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-000663-26-AT
(EUCTR)
25/04/200521/03/2005Immunsuppressive Therapy in Duchenne Muscular Dystrophy - DMD-CsAImmunsuppressive Therapy in Duchenne Muscular Dystrophy - DMD-CsA Duchenne Muscular DystrophyTrade Name: Sandimmun Optoral
Product Name: Sandimmun Optoral
Product Code: 29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00
Other descriptive name: Cyclosporin A
Trade Name: Decortin
Product Name: Decortin
Product Code: not available
Other descriptive name: Prednison
Universitätsklinik FreiburgNULLNot RecruitingFemale: no
Male: yes
150Phase 2;Phase 3Austria